Sid M. Patel
@SidPatelMD
Followers
801
Following
4K
Statuses
449
Cardiologist @BrighamWomens @HarvardMed and Investigator @TIMIStudyGroup
Boston, MA
Joined May 2016
RT @DrMarthaGulati: The amazing Dr. David Morrow talking at @SmidtHeart the improvement in care of patients with the evolution of the CICU…
0
10
0
RT @NEJM: In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activat…
0
53
0
More on the science of FXI inhibition in the editorial by @DFCapodanno and #DominickAngiolillo 👇🏼
0
0
2
RT @DFCapodanno: We authored the editorial “Science Behind the Study” for @NEJM, focusing on the AZALEA-TIMI 71 trial, a phase 2b study of…
0
17
0
RT @AndreZimerman: "Does lowering LDL-C to very low levels result in long-term cognitive impairment?" 🧠🫀 I've heard this question many tim…
0
140
0
RT @TIMIStudyGroup: Inopressors (particularly norepi) are the most frequently utilized vasoactive agents in CS; however, several factors in…
0
2
0
RT @TIMIStudyGroup: New data from the @CCCTNetwork & @UmichCVC shows significant variation in vasoactive medication use in the treatment of…
0
6
0
RT @TIMIStudyGroup: In contemporary CICUs, target temperatures for comatose cardiac arrest patients have shifted towards normothermia since…
0
5
0
RT @TIMIStudyGroup: "Study in 60k high-risk pts with polygenic 🧬 predisposition to #heartfailure identifies pts w/ ⬆️ incidence of HF well…
0
3
0
RT @cardiomet_CE: 10) So @SidPatelMD was in the room here at #AHA24 for @cardiomet_CE as @TIMIStudyGroup #fellow Samer Al Said @sameralsaid…
0
3
0
RT @TIMIStudyGroup: FXI inhibition w/abelacimab consistently ↓ bleeding vs. rivaroxaban, regardless of APT use, w/↑ ARR in bleeding in thos…
0
4
0